title: [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
abstract: OBJECTIVE
  To compare systemic anticoagulation with antiaggregation in patients with coronary stent, with regard to subacute occlusion, mean hospital staying and haemorrhagic complications.
  
  
  METHODS
  Seventy-five patients with coronary stent were treated with one of two different antithrombotic protocols. A group comprised of 34 patients (group A) received sodium heparin and acenocoumarin, plus acetylsalicylic acid (325 mg) and dipyridamole (225 mg). The remaining 41 patients (group B) were given antiplatelet agents, namely ticlopidine (125-250 mg) and aspirin (125 mg).
  
  
  RESULTS
  One case of group A (2.9%) showed thrombosis due to stent occlusion. No thrombotic complications were seen in the patients with antiplatelet drugs. Haemorrhagic complications were present in 11 group A patients (32.3%), and blood transfusion was necessary in 3 of them. Hemorrhage was present in 9 cases of group B (21.8%), and none of them needed blood transfusion. The mean number of days to achieve INR > 2 was 3.06 (1-11) in group and 2.02 (1-5) in group B.
  
  
  CONCLUSIONS
  Antiplatelet regimes appear as a good choice in coronary stent, in spite of the fact that the primary indication seems that of group A.
authors.affiliation: Servicio de Hematología, Hospital Clínico Universitario de Zaragoza.
authors.forename: T
authors.initials: T
authors.lastname: Iturbe
authors.forename: C
authors.initials: C
authors.lastname: Sánchez
authors.forename: J A
authors.initials: JA
authors.lastname: Moreno
authors.forename: T
authors.initials: T
authors.lastname: Olave
authors.forename: G
authors.initials: G
authors.lastname: Azaceta
authors.forename: M J
authors.initials: MJ
authors.lastname: Varo
authors.forename: E
authors.initials: E
authors.lastname: Civeira
authors.forename: J
authors.initials: J
authors.lastname: Peleato
authors.forename: R
authors.initials: R
authors.lastname: Cornudella
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003327:Coronary Disease / Q000601:surgery*; D004176:Dipyridamole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D012189:Retrospective Studies; D015607:Stents; D013927:Thrombosis / Q000517:prevention & control*; D013988:Ticlopidine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D006493:Heparin; D000074:Acenocoumarol; D013988:Ticlopidine; D001241:Aspirin